Disputable questions of statins antitumor effects in hemoblastoses

Antitumor drug treatment of hemoblastoses always takes into account the patient comorbidity. Due to frequent cardiovascular pathology and atherosclerosis, patients have take statins along with antitumor treatment. Experimental studies shown that inhibit cholesterol synthesis (necessary for vital activity malignant cells), isoprenylation RAS RHO oncogenes, proliferation leukemic cells. In addition, potentiation drugs effect by statins, sensitization leukemia lymphomas cells their effects were noted. when conducting a meta-analysis, it was found mortality among hematological malignancies taking is lower compared group not receiving statins. This fact probably explained only improvement in metabolism, but also indirect this drugs.